BR112020003541A2 - tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida - Google Patents

tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida Download PDF

Info

Publication number
BR112020003541A2
BR112020003541A2 BR112020003541-6A BR112020003541A BR112020003541A2 BR 112020003541 A2 BR112020003541 A2 BR 112020003541A2 BR 112020003541 A BR112020003541 A BR 112020003541A BR 112020003541 A2 BR112020003541 A2 BR 112020003541A2
Authority
BR
Brazil
Prior art keywords
patient
doses
bone
fact
acid sphingomyelinase
Prior art date
Application number
BR112020003541-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Cristina Scheidt-Puga
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112020003541A2 publication Critical patent/BR112020003541A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112020003541-6A 2017-08-24 2018-08-22 tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida BR112020003541A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
US62/549,732 2017-08-24
EP17306720 2017-12-07
EP17306720.8 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (1)

Publication Number Publication Date
BR112020003541A2 true BR112020003541A2 (pt) 2020-09-01

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003541-6A BR112020003541A2 (pt) 2017-08-24 2018-08-22 tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida

Country Status (17)

Country Link
US (2) US11898175B2 (enExample)
EP (1) EP3672622B1 (enExample)
JP (3) JP7216075B2 (enExample)
KR (2) KR20250025051A (enExample)
CN (2) CN118453843A (enExample)
AU (2) AU2018319565B2 (enExample)
BR (1) BR112020003541A2 (enExample)
CA (1) CA3073648A1 (enExample)
CO (1) CO2020001801A2 (enExample)
ES (1) ES2970423T3 (enExample)
IL (1) IL272757B2 (enExample)
MX (2) MX2020002106A (enExample)
NZ (1) NZ762860A (enExample)
PL (1) PL3672622T3 (enExample)
SG (1) SG11202001544VA (enExample)
TW (1) TWI791040B (enExample)
WO (1) WO2019038685A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
WO2006130769A2 (en) * 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
HK1207005A1 (en) 2012-03-02 2016-01-22 夏尔人类遗传性治疗公司 Compositions and methods for treating type iii gaucher disease
WO2014093354A1 (en) 2012-12-12 2014-06-19 Teva Pharmaceutical Industries Ltd. Fusion of human growth hormone and albumin, formulation and uses thereof
PL3004896T3 (pl) 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania

Also Published As

Publication number Publication date
MX2023010908A (es) 2023-09-27
AU2018319565A1 (en) 2020-04-09
KR20200044064A (ko) 2020-04-28
JP7216075B2 (ja) 2023-01-31
PL3672622T3 (pl) 2024-04-02
KR102769578B1 (ko) 2025-02-20
IL272757A (en) 2020-04-30
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
TWI791040B (zh) 2023-02-01
SG11202001544VA (en) 2020-03-30
JP2023052459A (ja) 2023-04-11
TW201919689A (zh) 2019-06-01
AU2018319565B2 (en) 2025-02-20
CN118453843A (zh) 2024-08-09
EP3672622B1 (en) 2023-11-08
WO2019038685A2 (en) 2019-02-28
CN111344003B (zh) 2024-05-07
CA3073648A1 (en) 2019-02-28
JP2024050732A (ja) 2024-04-10
JP7431356B2 (ja) 2024-02-14
KR20250025051A (ko) 2025-02-20
MX2020002106A (es) 2020-07-14
EP3672622A2 (en) 2020-07-01
IL272757B2 (en) 2024-07-01
WO2019038685A3 (en) 2019-05-02
US20210139868A1 (en) 2021-05-13
JP2020531527A (ja) 2020-11-05
CO2020001801A2 (es) 2020-04-01
US11898175B2 (en) 2024-02-13
NZ762860A (en) 2025-09-26
CN111344003A (zh) 2020-06-26
RU2020111649A (ru) 2021-09-24
AU2025203384A1 (en) 2025-05-29
US20240218338A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
US20240218338A1 (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
Osio et al. Improved final height with long‐term growth hormone treatment in Noonan syndrome
Schuchman et al. Types A and B niemann-pick disease
Marcucci et al. Gaucher disease and bone manifestations
Sasaki et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype–genotype correlation in Japanese patients with pachydermoperiostosis
Clarke et al. The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders
Otaify et al. Gnathodiaphyseal dysplasia: severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)
Lim et al. Association between body composition and pulmonary function in elderly people: the Korean Longitudinal Study on Health and Aging
Vissers et al. Whole‐exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D‐2‐hydroxyglutaric aciduria (MC‐HGA)
Aleem et al. Clinical and genomic characteristics of LAMA2 related congenital muscular dystrophy in a patients’ cohort from Qatar. A population specific founder variant
Ujhelyi et al. Bone mineral density and bone acquisition in children and young adults with cystic fibrosis: A follow‐up study
Rang et al. Re-imagining cystic fibrosis care: next generation thinking
Santi et al. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model
Kasapkara et al. The evaluation of skeletal manifestations in patients with Gaucher disease
Porey et al. A study of organophosphorus induced delayed myelopathy: uncommon sequelae of a common poisoning
Lee et al. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
Zhu et al. Serum myostatin levels are elevated in overweight patients
Kaur et al. A concise review on hypophosphatasia with case report
Youssef et al. Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt
Kaçmaz et al. Autoinflammatory bone diseases: Genetic mutations, clinical manifestations, and modern therapeutic approaches
Sugiyama et al. A Japanese single-center experience of the efficacy and safety of enzyme replacement therapy in childhood-onset hypophosphatasia
Laron et al. Recommended by ISPED and SIMA
Ding Microbiota Derived Metabolites as Modulators of Inflammation in Non-Alcoholic Fatty Liver Disease
Lierop Sclerostin: a key regulator of bone metabolism
BR122024007742A2 (pt) Uso de fosfatase alcalina recombinante no tratamento de ataques

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: SANOFI (FR)

B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025022093-0 PROTOCOLO 870250093130 EM 10/10/2025 18:33.